ClearPoint Neuro (CLPT) Hisse Özeti
Ticari aşamada bir tıbbi cihaz şirketi olan ClearPoint Neuro, Inc. Amerika Birleşik Devletleri'nde beyinde minimal invaziv cerrahi prosedürler gerçekleştirmeye yönelik platformların geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
CLPT Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ClearPoint Neuro, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$13.75 |
| 52 Haftanın En Yüksek Seviyesi | US$30.10 |
| 52 Haftanın En Düşük Seviyesi | US$8.27 |
| Beta | 1.31 |
| 1 Aylık Değişim | 11.70% |
| 3 Aylık Değişim | 19.25% |
| 1 Yıllık Değişim | 7.00% |
| 3 Yıllık Değişim | 95.87% |
| 5 Yıllık Değişim | -27.59% |
| Halka arzdan bu yana değişim | -54.17% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 09
CLPT: Biopharma Partnerships And Intracranial Programs Will Drive Future Upside Potential
Analysts have lifted their price target on ClearPoint Neuro by $2, reflecting updated assumptions around discount rates, profit margins, and long term price-to-earnings (P/E) expectations. What's in the News ClearPoint Neuro reaffirmed revenue guidance for 2026, maintaining an expected range of US$52 million to US$56 million.Anlatı Güncellemesi • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.Recent updates
Anlatı Güncellemesi • Jun 09
CLPT: Biopharma Partnerships And Intracranial Programs Will Drive Future Upside Potential
Analysts have lifted their price target on ClearPoint Neuro by $2, reflecting updated assumptions around discount rates, profit margins, and long term price-to-earnings (P/E) expectations. What's in the News ClearPoint Neuro reaffirmed revenue guidance for 2026, maintaining an expected range of US$52 million to US$56 million.Anlatı Güncellemesi • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.Seeking Alpha • Apr 29
ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook
Summary ClearPoint's stock has come under significant pressure in recent months following weaker 2026 revenue guidance and further regulatory uncertainty. Despite near-term headwinds, a step change in revenue remains likely as partner therapies are commercialized over the next few years. Independent of this, ClearPoint's forward revenue multiple looks increasingly reasonable given the company's strong competitive positioning and solid growth. Read the full article on Seeking AlphaAnlatı Güncellemesi • Apr 20
CLPT: Biopharma Partnerships Will Drive Future Intracranial Program Adoption
ClearPoint Neuro's analyst price target has shifted by $2 as analysts weigh the recent FDA feedback on a partner's program in relation to the company's more than 60 active biopharma relationships and multiple expedited intracranial programs. Analyst Commentary Bullish Takeaways Bullish analysts see the reset price target of $18 per share as supported by what they view as a base business valuation of $12 per share, with additional value tied to pipeline and execution on intracranial programs.Anlatı Güncellemesi • Apr 06
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption
Analysts have adjusted their price target on ClearPoint Neuro to $25.00, reflecting updated assumptions around the discount rate, margin expectations, and long term P/E benchmarks following recent research commentary. Analyst Commentary Recent research commentary on ClearPoint Neuro highlights a mix of optimism around the core business and caution linked to regulatory outcomes in partner programs, which feeds directly into updated valuation work and risk assumptions.Anlatı Güncellemesi • Mar 22
CLPT: Broad Biopharma Partnerships And Intracranial Programs Will Drive Future Upside
Analysts have raised their price target on ClearPoint Neuro to $25 from $24, citing the company’s broad base of more than 60 biopharma partners and multiple clinical-stage intracranial programs as key supports for the updated valuation framework. Analyst Commentary Recent research on ClearPoint Neuro reflects a mix of renewed optimism and lingering caution, with analysts updating their valuation work after regulatory feedback on a key partner trial and reassessing the base business.
Yeni Anlatı • Mar 21
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 06
CLPT: Broad Biopharma Partnerships Will Support Future Neurology Platform Upside
Analysts have reduced their fair value estimate for ClearPoint Neuro from $29 to $24 and highlighted a lower $18 Street price target, citing higher perceived risk after the FDA feedback on a partner program, while still pointing to a broad biopharma customer base and multiple clinical-stage collaborations as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the updated valuation from more than 60 active biopharma partners, which suggests a diversified customer base rather than reliance on a single program.
Yeni Anlatı • Mar 06
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • Nov 10
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
The ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price has softened a substantial 39% over the previous 30 days...Analiz Makalesi • Nov 03
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Sep 25
Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 84% after a shaky period...Analiz Makalesi • May 04
After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Those holding ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares would be relieved that the share price has rebounded 31% in...Seeking Alpha • Apr 29
ClearPoint Neuro: Fundamentals Continue To Strengthen
Summary ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. I continue to believe ClearPoint is an attractive investment opportunity, but its high revenue multiple, current lack of profitability and market volatility mean risk is elevated. Read the full article on Seeking Alpha
Yeni Anlatı • Mar 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.Analiz Makalesi • Feb 14
After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have continued their recent momentum with a 25% gain in the last month...Analiz Makalesi • Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders have had their patience rewarded with a 26% share price jump in the...Analiz Makalesi • Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Despite an already strong run, ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have been powering on, with a gain of 28...Analiz Makalesi • Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 26% after a shaky period...Analiz Makalesi • May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its latest first-quarter results and things are looking bullish...Seeking Alpha • Apr 25
ClearPoint Neuro: Macro-Induced Multiple Compression
Summary ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates. The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances. The recent capital raise should be sufficient to see the ClearPoint through to profitability. ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for ClearPoint Neuro is US$4.02 based on 2 Stage Free Cash Flow to Equity Current...Analiz Makalesi • Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) will be pleased this week, given that the stock price is up 19...Analiz Makalesi • Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ), is not the largest company out there, but it received a lot of attention from a...Analiz Makalesi • Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Key Insights The projected fair value for ClearPoint Neuro is US$10.27 based on 2 Stage Free Cash Flow to Equity...Hissedar Getirileri
| CLPT | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 3.4% | 6.1% | -3.3% |
| 1Y | 7.0% | -19.2% | 22.3% |
Getiri vs. Endüstri: CLPT geçen yıl % -19.2 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: CLPT geçen yıl % 22.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| CLPT volatility | |
|---|---|
| CLPT Average Weekly Movement | 11.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: CLPT hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: CLPT 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1998 | 172 | Joe Burnett | www.clearpointneuro.com |
Ticari aşamada bir tıbbi cihaz şirketi olan ClearPoint Neuro, Inc. Amerika Birleşik Devletleri'nde beyinde minimal invaziv cerrahi prosedürler gerçekleştirmeye yönelik platformların geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, baş sabitleme çerçevesi, bilgisayar iş istasyonu ve oda içi monitörü içeren ClearPoint donanımı gibi ClearPoint sistemleri ve SmartFrame yörünge cihazı, bir el kumandası ve ilgili aksesuarlar ile SmartFlow Neuro kanülünden oluşan ClearPoint tek kullanımlık malzemeleri sunmaktadır. Ayrıca cerrahi planlama, cihaz hizalama, hedefe navigasyon ve prosedür izlemede hekime rehberlik eden ClearPoint yazılımı; yumuşak dokuyu nekrotize etmek veya koagüle etmek için ClearPoint Prism Neuro lazer terapi sistemi ve aktif bir sıvı değişim platformu olan IRRAflow sistemi de sunmaktadır.
ClearPoint Neuro, Inc. Temel Bilgiler Özeti
| CLPT temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$407.56m |
| Kazançlar(TTM) | -US$29.07m |
| Gelir(TTM) | US$40.61m |
10.2x
P/S Oranı-14.2x
F/K OranıCLPT aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CLPT gelir tablosu (TTM) | |
|---|---|
| Gelir | US$40.61m |
| Gelir Maliyeti | US$15.30m |
| Brüt Kâr | US$25.32m |
| Diğer Giderler | US$54.38m |
| Kazançlar | -US$29.07m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.97 |
| Brüt Marj | 62.33% |
| Net Kâr Marjı | -71.57% |
| Borç/Özkaynak Oranı | 263.5% |
CLPT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/10 00:29 |
| Gün Sonu Hisse Fiyatı | 2026/06/10 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ClearPoint Neuro, Inc. 7 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |